Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06737172Enrolling By Invitation

Functional and Structural Outcomes Following Childhood Bone or Soft Tissue Sarcomas of the Lower Extremity

Role: collaborator

NCT06743958Not ApplicableEnrolling By Invitation

Prehabilitation in Childhood Soft Tissue or Bone Sarcomas

Role: collaborator

NCT06642506Active Not Recruiting

Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma

Role: collaborator

NCT00561691Completed

Nimotuzumab in Children With Intrinsic Pontine Glioma

Role: collaborator

NCT00753246Phase 3Completed

Nimotuzumab in Adults With Glioblastoma Multiforma

Role: collaborator

NCT00561873Completed

Nimotuzumab in Children With HGG

Role: collaborator

All 6 trials loaded